Copyright
©The Author(s) 2019.
World J Diabetes. Feb 15, 2019; 10(2): 114-132
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Table 14 Change in serum triglycerides in individual studies
| Study | Serum triglycerides (mg/dL) | P value | P value between groups | ||
| Group | Baseline | Study completion | |||
| Kuchay et al[11] | Empagliflozin | 201.0 (124.0) | 155.0 (52.0) | 0.01 | 0.678 |
| Control | 212.0 (115.0) | 175.0 (43.0) | 0.019 | ||
| Ito et al[12] | Ipragliflozin | 166.9 (76.4) | 143.4 (81.4) | < 0.05 | 0.938 |
| Pioglitazone | 188.4 (148.8) | 169.3 (131.3) | Non-significant | ||
| Eriksson et al[14] | Placebo | 169.2 (84.1) | -11.5 (45.6)1 | - | - |
| Omega-3 CA | 186.9 (81.5) | -15.9 (47.4)1 | - | Non-significant2 | |
| Dapagliflozin | 178.0 (103.6) | +14.2 (40.5)1 | - | Non-significant2 | |
| O + D | 168.3 (72.6) | -25.7 (57.1)1 | - | Non-significant2 | |
| Ohki et al[15] | Ipragliflozin | 148.0 (107.0, 222.) | 145.0 (114.0, 172.0) | 0.75 | - |
| Seko et al[16] | SGLT-2 inhibitor | 153.8 (15.9) | 137.8 (10.5) | 0.236 | - |
| Sitagliptin | 193.4 (25.2) | 191.1 (23.8) | 0.986 | ||
| Sumida et al[18] | Luseogliflozin | 158.1 (110.5) | 129.4 (59.5) | 0.062 | - |
- Citation: Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132
- URL: https://www.wjgnet.com/1948-9358/full/v10/i2/114.htm
- DOI: https://dx.doi.org/10.4239/wjd.v10.i2.114